Stay updated with breaking news from Controlled Equity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
*Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel in patients with Fragile X syndrome; topline results expected first-half 2024 *$44.4 million in cash and cash... | May 16, 2023
Item 1.01. Entry into a Material Definitive Agreement. Guggenheim Taxable Municipal Bond & Investment Grade Debt Trust has entered into a Controlled Equity OfferingSM Sales Agreement, dated... | April 21, 2023
GUGGENHEIM TAXABLE MUNICIPAL BOND & INVESTMENT GRADE DEBT TRUST COMMON SHARES SECOND AMENDMENT TO CONTROLLED EQUITY... | April 21, 2023
Investegate announcements from Nyxoah, Nyxoah Raises $3 Million from its At-the-Market Equity Offering
Item 1.01. Entry into a Material Definitive Agreement. Guggenheim Strategic Opportunities Fund has entered into a Controlled Equity OfferingSM Sales Agreement, dated July 1, 2019, as amended by... | April 11, 2023